All In Biotech

Drug Trial Radar · NCT05702450

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

A Randomized, Open, Parallel Phase I Clinical Study on the Comparison of Pharmacokinetics Characteristics of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Mar 22, 2023

Primary completion

Jul 26, 2023

Study completion Jul 26, 2023

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.

Conditions

  • Healthy

Interventions

  • CM310Biological

    CM310 Recombinant Humanized Monoclonal Antibody Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic: the maximum concentration (Cmax)Time frame: up to 57 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PKUCare Luzhong Hospital

    Zibo, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.